| scholarly article | Q13442814 |
| P2093 | author name string | Alessandro M Vannucchi | |
| Claire Harrison | |||
| P2860 | cites work | JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis | Q24609999 |
| Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders | Q24657681 | ||
| Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805 | Q27662886 | ||
| Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. | Q27851427 | ||
| CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients | Q28238474 | ||
| A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera | Q28241887 | ||
| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis | Q29614337 | ||
| Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders | Q29614510 | ||
| A gain-of-function mutation of JAK2 in myeloproliferative disorders | Q29618851 | ||
| Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders | Q29618853 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. | Q33371084 | ||
| Pomalidomide is active in the treatment of anemia associated with myelofibrosis | Q33385644 | ||
| Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis | Q33387514 | ||
| A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms | Q33390255 | ||
| Biology and chemistry of thrombopoietic agents | Q33390625 | ||
| Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis | Q33391404 | ||
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 | ||
| DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 | ||
| JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 | ||
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
| Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls | Q33843390 | ||
| CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | Q33944270 | ||
| Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 | ||
| Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia | Q83893178 | ||
| Long-term outcome of treatment with ruxolitinib in myelofibrosis | Q85087797 | ||
| Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms | Q95779600 | ||
| Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. | Q34074931 | ||
| HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans | Q34162151 | ||
| Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial | Q34162867 | ||
| SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. | Q34194226 | ||
| Some speculations on the myeloproliferative syndromes. | Q34296252 | ||
| Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon α specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells | Q34360366 | ||
| MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia | Q34770384 | ||
| Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model | Q35849674 | ||
| Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. | Q36003480 | ||
| DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms | Q36267848 | ||
| International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). | Q36468734 | ||
| Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550) | Q37139740 | ||
| Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. | Q37412790 | ||
| Advances in understanding and management of myeloproliferative neoplasms | Q37445395 | ||
| Allogeneic stem cell transplantation for myelofibrosis in 2012. | Q37998567 | ||
| Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. | Q39719120 | ||
| Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity | Q39779533 | ||
| Characterization of murine JAK2V617F-positive myeloproliferative disease | Q40200859 | ||
| The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis | Q40265956 | ||
| Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. | Q41283205 | ||
| Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia | Q42720284 | ||
| LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations | Q42931701 | ||
| Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. | Q43031345 | ||
| Taxing sugar-sweetened beverages | Q43180928 | ||
| Mutations of ASXL1 gene in myeloproliferative neoplasms. | Q43456344 | ||
| Decitabine is an effective treatment of idiopathic myelofibrosis | Q46169214 | ||
| Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients | Q46543499 | ||
| Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia | Q46562604 | ||
| 5-Azacitidine has limited therapeutic activity in myelofibrosis | Q46570218 | ||
| Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice | Q46832173 | ||
| Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type | Q47174502 | ||
| Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms | Q47960630 | ||
| Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. | Q50528661 | ||
| Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. | Q51025938 | ||
| Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. | Q51758016 | ||
| Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. | Q54426186 | ||
| Possible new LNK mutations in myeloproliferative neoplasms. | Q54559825 | ||
| EZH2 mutational status predicts poor survival in myelofibrosis. | Q54560112 | ||
| From palliation to targeted therapy in myelofibrosis. | Q54649910 | ||
| Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 | ||
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 | ||
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 | ||
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment | Q80866784 | ||
| General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G) | Q81685445 | ||
| p53 lesions in leukemic transformation | Q83352019 | ||
| P433 | issue | 6 | |
| P921 | main subject | ruxolitinib | Q7383611 |
| P304 | page(s) | 341-354 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Therapeutic advances in hematology | Q26842172 |
| P1476 | title | Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians | |
| P478 | volume | 3 |
| Q96134093 | Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell lung cancer |
| Q38187675 | Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. |
| Q42609653 | Imatinib and ruxolitinib association: first experience in two patients |
| Q90406871 | Norovirus Replication in Human Intestinal Epithelial Cells Is Restricted by the Interferon-Induced JAK/STAT Signaling Pathway and RNA Polymerase II-Mediated Transcriptional Responses |
| Q92979173 | Overexpression of PSAT1 promotes metastasis of lung adenocarcinoma by suppressing the IRF1-IFNγ axis |
| Q47097176 | Ruxolitinib in Myelofibrosis and Polycythemia Vera |
| Q37304113 | Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency |
| Q90745265 | The Promise of JAK Inhibitors for Treatment of Sarcoidosis and Other Inflammatory Disorders with Macrophage Activation: A Review of the Literature |
| Q50099353 | The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy Subjects |
| Q88288451 | [Biobanking requirements from the perspective of the clinician : Experiences in hematology and oncology] |
Search more.